➡️Astepro Allergy (azelastine) Nasal Spray

Date of Approval: June 17, 2021
Company: Bayer HealthCare LLC
Treatment for: Allergic Rhinitis

Astepro Allergy (azelastine) is a nasal antihistamine for the treatment of seasonal allergic rhinitis.

https://news.1rj.ru/str/ppdprogram

➡️Wegovy (semaglutide) Injection

Date of Approval: June 4, 2021
Company: Novo Nordisk
Treatment for: Obesity

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are overweight (BMI ≥27 kg/m2) or obese (BMI ≥30 kg/m2).

https://news.1rj.ru/str/ppdprogram

➡️Soaanz (torsemide) Tablets

Date of Approval: June 14, 2021
Company: Sarfez Pharmaceuticals
Treatment for: Edema

Soaanz (torsemide) is a loop diuretic indicated for the treatment of edema associated with heart failure or renal disease in adults.

https://news.1rj.ru/str/ppdprogram

➡️Verkazia (cyclosporine) Ophthalmic Emulsion

Date of Approval: June 23, 2021
Company: Santen Inc.
Treatment for: Vernal Keratoconjunctivitis

Verkazia (cyclosporine) is a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.

https://news.1rj.ru/str/ppdprogram

➡️Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Injection

Date of Approval: June 30, 2021
Company: Jazz Pharmaceuticals plc
Treatment for: Acute Lymphoblastic Leukemia

Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).

https://news.1rj.ru/str/ppdprogram

➡️Kerendia (finerenone) Tablets

Date of Approval: July 9, 2021
Company: Bayer
Treatment for: Chronic Kidney Disease Associated with Type 2 Diabetes

Kerendia (finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist (MRA) for the treatment of patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

https://news.1rj.ru/str/ppdprogram

➡️(fexinidazole) Tablets

Date of Approval: July 16, 2021
Company: Drugs for Neglected Diseases Initiative
Treatment for: Trypanosomiasis

Fexinidazole is a nitroimidazole antibacterial indicated for the treatment of human African trypanosomiasis (African sleeping sickness) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg.

https://news.1rj.ru/str/ppdprogram

➡️Bylvay (odevixibat) Capsules

Date of Approval: July 20, 2021
Company: Albireo Pharma, Inc.
Treatment for: Progressive Familial Intrahepatic Cholestasis (PFIC)

Bylvay (odevixibat) is an ileal bile acid transport (IBAT) inhibitor for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC).

https://news.1rj.ru/str/ppdprogram

➡️Twyneo (tretinoin and benzoyl peroxide) Cream

Date of Approval: July 26, 2021
Company: Sol-Gel Technologies, Ltd.
Treatment for: Acne

Twyneo (tretinoin and benzoyl peroxide) is a topical retinoid and antibacterial fixed-dose combination for the treatment of acne vulgaris in adults and children 9 years of age and older.

https://news.1rj.ru/str/ppdprogram

➡️Korsuva (difelikefalin) Injection

Date of Approval: August 23, 2021
Company: Cara Therapeutics, Inc.
Treatment for: Chronic Kidney Disease-Associated Pruritus

Korsuva (difelikefalin) is a selective peripheral kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD).

https://news.1rj.ru/str/ppdprogram

➡️Skytrofa (lonapegsomatropin-tcgd) for Injection

Date of Approval: August 25, 2021
Company: Ascendis Pharma A/S
Treatment for: Pediatric Growth Hormone Deficiency

Skytrofa (lonapegsomatropin-tcgd) is a human growth hormone used once-weekly for the treatment of pediatric growth hormone deficiency.

https://news.1rj.ru/str/ppdprogram

➡️Trudhesa (dihydroergotamine mesylate) Nasal Spray

Date of Approval: September 2, 2021
Company: Impel NeuroPharma, Inc.
Treatment for: Migraine

Trudhesa (dihydroergotamine mesylate) is a nasally administered dihydroergotamine (DHE) formulation for the acute treatment of migraine with or without aura in adults.

https://news.1rj.ru/str/ppdprogram

➡️Tivdak (tisotumab vedotin-tftv) Lyophilized Powder for Injection

Date of Approval: September 20, 2021
Company: Seagen Inc.
Treatment for: Cervical Cancer

Tivdak (tisotumab vedotin-tftv) is a tissue factor-directed antibody and microtubule inhibitor conjugate for the treatment of patients with recurrent or metastatic cervical cancer.

https://news.1rj.ru/str/ppdprogram

➡️Opzelura (ruxolitinib) Cream

Date of Approval: September 21, 2021
Company: Incyte
Treatment for: Atopic Dermatitis

Opzelura (ruxolitinib) cream is a topical Janus kinase (JAK) inhibitor used for the treatment of atopic dermatitis.

https://news.1rj.ru/str/ppdprogram

➡️Qulipta (atogepant) Tablets

Date of Approval: September 28, 2021
Company: AbbVie Inc.
Treatment for: Migraine Prevention

Qulipta (atogepant) is an oral, calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of episodic migraine in adults.

https://news.1rj.ru/str/ppdprogram

➡️Tavneos (avacopan) Capsules

Date of Approval: October 7, 2021
Company: ChemoCentryx, Inc.
Treatment for: ANCA-Associated Vasculitis

Tavneos (avacopan) is a complement 5a receptor (C5aR) antagonist for the adjunctive treatment of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.

https://news.1rj.ru/str/ppdprogram

➡️Zimhi (naloxone hydrochloride) Injection

Date of Approval: October 15, 2021
Company: Adamis Pharmaceuticals Corporation
Treatment for: Opioid Overdose

Zimhi (naloxone hydrochloride) is a high-dose formulation of the approved opioid antagonist naloxone for use in the treatment of opioid overdose.

https://news.1rj.ru/str/ppdprogram

➡️Tyrvaya (varenicline) Nasal Spray

Date of Approval: October 15, 2021
Company: Oyster Point Pharma, Inc.
Treatment for: Dry Eye Disease

Tyrvaya (varenicline) is a nasally administered selective cholinergic agonist for the treatment of the signs and symptoms of dry eye disease.

https://news.1rj.ru/str/ppdprogram

➡️Scemblix (asciminib) Tablets

Date of Approval: October 29, 2021
Company: Novartis
Treatment for: Chronic Myelogenous Leukemia

Scemblix (asciminib) is a tyrosine kinase inhibitor used for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).

https://news.1rj.ru/str/ppdprogram

➡️Eprontia (topiramate) Oral Solution

Date of Approval: November 5, 2021
Company: Azurity Pharmaceuticals, Inc.
Treatment for: Epilepsy, Migraine Prevention

Eprontia (topiramate) is a ready-to-use liquid formulation of the approved anticonvulsant topiramate for use in the treatment of epilepsy and the preventive treatment of migraine.

https://news.1rj.ru/str/ppdprogram

➡️Xaciato (clindamycin phosphate) Vaginal Gel - formerly DARE-BV1

Date of Approval: December 7, 2021
Company: Daré Bioscience, Inc.
Treatment for: Bacterial Vaginosis

Xaciato (clindamycin phosphate) is a topical lincosamide antibacterial for the vaginally-administered treatment of bacterial vaginosis in female patients 12 years of age and older.

https://news.1rj.ru/str/ppdprogram